On November 7, 2025, Aarti Drugs Limited released its financial highlights for the second quarter and the first half of the fiscal year 2026. As mandated by the Securities and Exchange Board of India (SEBI) regulations, the company's presentation was submitted to both the BSE and NSE, with respective codes 524348 and symbol AARTIDRUGS. This disclosure marks an important reporting period for Aarti Drugs, providing investors and stakeholders with insights into the company’s performance and strategic direction.

The investor presentation outlines several key financial metrics and business highlights for Q2 and H1 FY26. Although specific figures were not disclosed in the brief, the report emphasizes Aarti Drugs' ongoing commitment to transparency and accountability in its financial reporting. The company aims to set a benchmark for future growth, leveraging its market position and operational efficiencies. Aarti Drugs is also keen to highlight its growth drivers and industry strengths, which it believes will support sustained performance in a competitive landscape.

In preparing this document, Aarti Drugs cautions investors about potential risks associated with forward-looking statements, which may not guarantee future performance. The company recognizes the various uncertainties that could impact its results, including economic fluctuations and market dynamics. As such, Aarti Drugs does not assume any obligation to update these projections, and stakeholders are advised to consider a range of factors when assessing the company's outlook. This emphasis on risk management reflects Aarti's proactive approach to navigating the complexities of the pharmaceutical industry.